



November 1, 2017

Steven C. Greenway, MD
 Assistant Professor of Pediatrics
 Alberta Children's Hospital
 Department of Pediatric Cardiology
 2888 Shaganappi Trail NW
 Calgary, AB T3B 6A8
 Canada

Dear Dr. Greenway,

The Children's Cardiomyopathy Foundation (the "Foundation") is pleased to inform you ("Grantee") that your proposed research project, ***Modeling Novel Therapeutics for DCMA, a Mitochondrial Cardiomyopathy***, has been approved for a grant of USD \$49,184. This grant, which will be made payable to University of Calgary, is contingent on the following grant terms and conditions:

1. **Grant Period:** Grants are for one year of funding beginning from the time funds are received until the same time the following year. Extensions will be considered for delays if a valid reason is submitted in writing before the end of the grant period.
1. **Grant Payments:** Upon receipt of a signed Foundation letter of agreement and letter of approval by the Grantee's Institutional Review Board (IRB) or Institutional Animal Care and Use Committee (IACUC), the Foundation will award 50% of the grant award amount as startup funds. The remaining 3 payments will be based upon meeting certain milestones and deliverables as outlined below. Grant payments will be contingent on the number of patients enrolled and samples acquired during the study period. Final payment is dependent on achieving the aims outlined in the proposed research study, submission of a detailed final report and verification that research findings are presented at a recognized medical conference and/or a manuscript has been submitted or accepted for publication in a peer reviewed medical or scientific journal.

- Signing of grant acknowledgement letter and submission of IRB approval letter \$24,600
- Submission of mid-year progress report and expenditure summary to CCF \$12,294
- Submission of final report and confirmation that research findings are to be presented at a recognized medical conference and/or manuscript has been submitted for publication in a peer reviewed medical/scientific journal \$12,290

TOTAL GRANT AWARD	USD \$49,184
-------------------	--------------

3. Progress Reports: The awarded Grantee shall provide a six-month progress report as well as a twelve-month progress report upon completion of the grant. Each report should include an accounting summary of grant expenditures and a narrative account of what was accomplished by the grant, including a detailed description of progress made towards achieving the research goals and any significant findings. If for some reason the grant period is extended beyond one year, a progress report and accounting summary shall be provided to the Foundation every six months unless otherwise noted. One year after the completion of the grant, the Grantee will be asked to provide a list of presentations, publications and/or subsequent funding received as a result of the Foundation's grant support.
4. Site of Project: The Foundation awards funding to public or private universities, hospitals and biomedical research institutions in the United States or Canada. The research shall take place only in the research facility specified in the submitted research proposal. In the event the Grantee leaves his or her affiliated institution, the Grantee shall immediately notify the Foundation of the changes and submit a status report and accounting of the funds spent to date. It is the responsibility of the Grantee to make necessary arrangements with their institution to permit transfer of any unused Foundation research funds to the Grantee's new institution.
5. Expenditures: The grant is made only for the purposes stated in the research proposal and according to the proposed research budget. Any changes in a budget category equal to or greater than 10% of the total research grant amount must receive prior approval by the Foundation before funds are expended. The grant covers direct costs only, and funds may not be used for institutional overhead, construction or renovation, purchase of major capital equipment, office equipment or furniture, travel, tuition fees, journal subscriptions, dues or membership, or equipment service contracts. At the end of the grant period, any unused funds shall be promptly returned to the Foundation.
6. Grants Administration: The grant funds shall be physically segregated, and such funds shall be shown separately on the Grantee's books for ease of reference and verification. Records of receipts and expenditures under the grant, as well as copies of reports submitted to the Foundation, should be kept for a reasonable period of time following completion of such receipts and expenditures.
7. Institutional Research Approval: All Foundation-funded research projects must conform to federal regulation requiring that all institutions maintain appropriate policies and procedures for the protection of the rights and welfare of human subjects and the safe and humane treatment of animals used for research. A letter of approval from the Grantee's Institutional Review Board (IRB) or Institutional Animal Care and Use Committee (IACUC) must be provided to the Foundation before the start of the research study.
8. Liability: The Grantee assumes sole responsibility for conducting the research and supervising the work of co-investigators associated with the study, and is therefore responsible for any negligent acts or omissions that may arise in connection with their research study. The Grantee and Grantee's institution shall indemnify and hold harmless the Foundation, its Board, advisors, agents and constituents from any claim, judgment, award, damage, settlement, liability, negligence or malpractice arising from accepting the Foundation's grant, expending or applying grant funds, or in carrying out the research study supported by the grant.
9. Grant Suspension or Cancellation: The Foundation reserves the right to suspend or cancel the funding agreement at any time at its sole discretion for failure of the Grantee to abide by the


Foundation's grant terms. Upon receipt of a written notice of project suspension or cancellation from the Foundation, the Grantee should prepare and submit a project status report and accounting summary of funds expended to date. All unused funds must be returned to the Foundation immediately upon its request. A Grantee may terminate a grant by sending written notice to the Foundation stating the reason and providing a project status report and accounting summary of funds expended. The Grantee should make arrangements to promptly return unused funds to the Foundation.

10. Dissemination of Findings: All findings resulting from research supported by the Foundation shall be made public, preferably through recognized national medical meetings and peer-reviewed journal articles. Any scientific data resulting from research funded by the Foundation shall be made available to other researchers and non-commercial laboratories in a timely manner at a no charge or at cost basis. If it has been determined that the findings will not be published, the Grantee and the Foundation shall discuss other options for dissemination of the data to the public and medical/scientific community.
11. Presentation and Publication Acknowledgement: All presentations and publications related to research funded in part or in whole by the Foundation's research grant must cite the Children's Cardiomyopathy Foundation (full name of foundation) as a source of funding. The Foundation shall be notified when a presentation or publication related to the funded research has been accepted or confirmed, and a PDF file of the final abstract or publication shall be forwarded to the Foundation when available.
12. References to Work: Both the Foundation and the Grantee may include general, non-confidential information about the research grant in announcements to the general public and their constituents. For specific print or internet references, such as communication materials or press releases, the Grantee or Grantee's institution must acknowledge the Foundation's involvement and notify the Foundation before distribution. Similarly, announcements about the study findings must be reviewed by the Grantee before distribution by the Foundation.
13. Amendments: This agreement constitutes the entire funding agreement between the parties with respect to the subject matter hereof and it may not be amended or modified except by writing and signed by both parties hereto.

If this letter correctly sets forth your understanding of the arrangements made regarding this grant, please sign two copies of this letter and return one copy to CCF along with your institution's IRB or IACUC letter of approval. The Foundation will make the first installment of the grant available upon receipt of these two items.

We are proud to support your important work in the field of pediatric cardiomyopathy. We hope that studies such as yours will help to advance medical knowledge on this rare and devastating disease in children. On behalf of the Children's Cardiomyopathy Foundation, I extend my best wishes for the success of your research project.

Sincerely yours,



Lisa Yue
President, Children's Cardiomyopathy Foundation

Received and Agreed to:

Signed: _____

Steven C. Greenway, MD
Assistant Professor of Pediatrics
Alberta Children's Hospital

Date: November 6, 2017